Eligibility of monoclonal antibody-based therapy for patients with severe asthma: a Canadian cross-sectional perspective

• Short report
• Open Access

• Samira JeimyEmail authorView ORCID ID profile,
• Michael William Tsoulis,
• Julie Hachey and
• Harold Kim

Allergy, Asthma & Clinical Immunology201814:68

https://doi.org/10.1186/s13223-018-0301-6

Abstract

Background

Based on immunologic phenotypes underlying asthma, use of monoclonal antibody based therapies is becoming the new standard of care for severe, corticosteroid refractory clinical symptoms. Patients may qualify for one or more of these targeted treatments, based on clinical characteristics and approved indications.

Association of Fatality Risk With Value-Based Drug Pricing of Epinephrine Autoinjectors for Children With Peanut Allergy. A Cost-effectiveness Analysis

Original Investigation 

Allergy

Marcus Shaker, MD, MS^1,2; Matthew Greenhawt, MD, MBA, MSc³

Author Affiliations Article Information

JAMA Netw Open. 2018;1(7):e184728. doi:10.1001/jamanetworkopen.2018.4728

Key Points

Question  Given that wide variation exists in costs of epinephrine autoinjectors used to treat community anaphylaxis, can we define a value-based price for such devices?

Findings  In this economic evaluation of community anaphylaxis treatment, the ceiling value-based price for an epinephrine autoinjector was $24, assuming a personal autoinjector prescription decreases the risk for food allergy fatality by 10-fold.

Meaning  Epinephrine is central to managing anaphylaxis, and $24 personal autoinjectors are cost-effective for community-based anaphylaxis management.

Subcutaneous immunotherapy induces alterations in monocytes and dendritic cells homeostasis in allergic rhinitis patients

Allergy, Asthma & Clinical Immunology

 
• Research
• Open Access

• Letícia Sousa,
• Carmen Martín-Sierra,
• Celso Pereira,
• Graça Loureiro,
• Beatriz Tavares,
• Susana Pedreiro,
• António Martinho and
• Artur PaivaEmail author

Allergy, Asthma & Clinical Immunology201814:45

https://doi.org/10.1186/s13223-018-0271-8

Abstract

Background

Specific subcutaneous immunotherapy (SCIT) can achieve long-term remission in patients with allergic rhinitis (AR) through complex and still unknown mechanisms. The aim of this study is to evaluate the effect of SCIT over CD16+ and CD16− monocytes, myeloid (mDCs) and plasmacytoid dendritic cells (pDCs) in patients with AR, comparatively to pharmacological standard treatment (non-SIT).

Sweet syndrome: a rare feature of ANCA-associated vasculitis or unusual consequence of azathioprine-induced treatment

Allergy, Asthma & Clinical Immunology


• Case report
• Open Access

• A. U. Arun KumarView ORCID ID profile,
• Mohamed E. Elsayed,
• Ahmed Alghali,
• Alaa A. Ali,
• Husham Mohamed,
• Wael Hussein,
• Catriona Hackett,
• Niamh Leonard and
• Austin G. StackEmail author

Allergy, Asthma & Clinical Immunology201814:46

Abstract

Background

Sweet syndrome is a rare skin condition characterised by fever, neutrophilia, and tender erythematous skin lesions and has been reported to occur in association with anti-neutrophil cytoplasmic antibodies (ANCA) as well as complicate treatment with azathioprine therapy. Azathioprine, a relatively safe immunosuppressive, is frequently used to maintain disease remission in the treatment of ANCA-associated vasculitis.

Unraveling the enigma: elucidating the relationship between the physicochemical properties of aluminium-based adjuvants and their immunological mechanisms of action

Allergy, Asthma & Clinical Immunology                      
• Review
• Open Access 
• Emma Shardlow,
• Matthew Mold and
• Christopher ExleyEmail authorView ORCID ID profile
Allergy, Asthma & Clinical Immunology201814:80
   
Abstract
Aluminium salts are by far the most commonly used adjuvants in vaccines. There are only two aluminium salts which are used in clinically-approved vaccines, Alhydrogel® and AdjuPhos®, while the novel aluminium adjuvant used in Gardasil® is a sulphated version of the latter.

Incidence Trends of Atopic Dermatitis in Infancy and Early Childhood in a Nationwide Prescription Registry Study in Norway

Original Investigation 

Dermatology

November 2, 2018

Cathrine H. Mohn, MD¹; Hege Salvesen Blix, MSc, Pharm, PhD²; Jon Anders Halvorsen, MD, PhD³; et alPer Nafstad, MD, PhD^4,5; Morten Valberg, MSc, PhD⁶; Per Lagerløv, MD, PhD¹

Author Affiliations Article Information

JAMA Network Open. 2018;1(7):e184145. doi:10.1001/jamanetworkopen.2018.4145

Key Points

Question  Is the incidence rate of pediatric atopic dermatitis still increasing?

Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia

Original Investigation 

Immunology

November 2, 2018

Sara Barmettler, MD¹; Mei-Sing Ong, PhD²; Jocelyn R. Farmer, MD, PhD¹; et alHyon Choi, MD, DrPH³; Jolan Walter, MD, PhD^4,5

Author Affiliations Article Information

JAMA Netw Open. 2018;1(7):e184169. doi:10.1001/jamanetworkopen.2018.4169

Key Points

Question  In patients receiving rituximab, what are the current rates of screening and recognition of hypogammaglobulinemia, and what are the infectious risks and predictors for increased mortality?

Macrolide antibiotics in the treatment of chronic rhinosinusitis: evidence from a meta-analysis

 
• Vol 10, No 10 (October 2018)

Authors: Shen Shen, Hongfei Lou, Chengshuo Wang, Luo Zhang

Abstract

Background: The purpose of this study was to systematically assess the subjective and objective outcomes of macrolide therapy for chronic rhinosinusitis (CRS).
Methods: PubMed, Embase and Cochrane databases were searched for clinical trials detailing the effects of macrolide therapy in patients with CRS and published up to December 2017. Sino-Nasal Outcome Test (SNOT), endoscopic scores and computed tomography scans (CT) scores were assessed by mean difference (MD) or standardized mean difference (SMD) with 95% confidence interval. Subgroup analyses were performed to evaluate the source of heterogeneity according to study design and geographic locations. I2 metric was used to assess the heterogeneity.